TRANSCEND LTE: A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE) (clinicaltrials.gov) - Oct 1, 2026 - P3 | N=201 | Enrolling by invitation | Sponsor: Biogen | Trial completion date: May 2031 ➔ Dec 2031 | Trial primary completion date: May 2031 ➔ Dec 2031
Trial completion date • Trial primary completion date • Antibody-mediated Rejection • Inflammation • Transplantation
|